Cover Image
Market Research Report

Europe Atopic Dermatitis Drugs Market Forecast 2019-2027

Published by Inkwood Research Product code 626307
Published Content info 72 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Atopic Dermatitis Drugs Market Forecast 2019-2027
Published: October 8, 2018 Content info: 72 Pages
Description

KEY FINDINGS

Experts have estimated that a high number of people belonging to the European population suffer from conditions such as conjunctivitis, skin allergies and food allergies. The market for atopic dermatitis drugs in Europe is, therefore expected to showcase a CAGR of 3.30% over the forecast period of 2019-2027.

MARKET INSIGHTS

Researchers have suggested that with the growing prices of the latest medications and increasing number of patients, the dependence on these medicines and drugs to treat symptoms is expected to increase. One of the fastest growing markets for atopic dermatitis drugs in the European market is Russia. According to forecasts, the country is expected to have the highest CAGR by 2027. The most probable reason for this might be poor hygienic conditions and heavy industrialization in the area.

COMPETITIVE INSIGHTS

Leading market players include Aqua Pharmaceuticals (An Almirall Company), Allergan Plc, Astellas Pharma Inc., Biofrontera Ag, Bayer Ag, Bristol-Myers Squibb, Encore Dermatology, Stiefel Laboratories, Inc, Galderma Sa, Meda Pharmaceuticals (Mylan N.V.), Leo Pharma,Novartis Ag, Regeneron Pharmaceuticals, Pfizer, Valent Pharmaceutical Inc and Sanofi Sa.

Table of Contents
Product Code: 16694

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
    • 3.2.2. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
    • 4.1.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
    • 4.1.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
    • 4.2.2. GENERIC COMPETITION
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
    • 4.3.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
    • 4.3.3. GROWING FOCUS ON NOVEL DRUGS
  • 4.4. MARKET CHALLENGES
    • 4.4.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
    • 4.4.2. HIGHLY GENERICIZED MARKET
    • 4.4.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE

5. MARKET SEGMENTATION

  • 5.1. MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
    • 5.1.1. TOPICAL
    • 5.1.2. ORAL
    • 5.1.3. INJECTIBLES
  • 5.2. MARKET BY DRUG CLASS 2019-2027
    • 5.2.1. TOPICAL ANTIBIOTICS
    • 5.2.2. TOPICAL ANTIHISTAMINES
    • 5.2.3. TOPICAL CORTICOSTEROIDS
    • 5.2.4. TOPICAL MOISTURIZERS/EMOLLIENTS
    • 5.2.5. TOPICAL CALCINEURIN INHIBITORS
    • 5.2.6. IMMUNOMODULATORS
    • 5.2.7. OFF-LABEL THERAPIES
    • 5.2.8. SYSTEMIC AGENTS
    • 5.2.9. PDE4 INHIBITOR
    • 5.2.10. INTERLEUKIN INHIBITOR

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCES ANALYSIS
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE
    • 6.1.3. BARGAINING POWER OF SUPPLIERS
    • 6.1.4. BARGAINING POWER OF BUYERS
    • 6.1.5. THREAT OF COMPETITIVE RIVALRY
  • 6.2. OPPORTUNITY MATRIX
  • 6.3. PIPELINE ANALYSIS
  • 6.4. LEGAL, POLICY AND REGULATORY ISSUES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. EUROPE
    • 7.1.1. GERMANY
    • 7.1.2. FRANCE
    • 7.1.3. THE UNITED KINGDOM
    • 7.1.4. RUSSIA
    • 7.1.5. ITALY
    • 7.1.6. REST OF EUROPE

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
    • 8.1.1. COMPANY OVERVIEW
    • 8.1.2. PRODUCT PORTFOLIO
    • 8.1.3. SWOT ANALYSIS
    • 8.1.4. STRATEGIC INITIATIVES
  • 8.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SWOT ANALYSIS
  • 8.3. ASTELLAS PHARMA INC.
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SWOT ANALYSIS
    • 8.3.4. STRATEGIC INITIATIVES
  • 8.4. BAYER AG
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SWOT ANALYSIS
    • 8.4.4. STRATEGIC INITIATIVES
  • 8.5. BIOFRONTERA AG
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SWOT ANALYSIS
  • 8.6. BRISTOL-MYERS SQUIBB
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SWOT ANALYSIS
  • 8.7. STIEFEL LABORATORIES, INC
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SWOT ANALYSIS
  • 8.8. ENCORE DERMATOLOGY
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCT PORTFOLIO
    • 8.8.3. SWOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. GALDERMA SA
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. PRODUCT PORTFOLIO
    • 8.9.3. SWOT ANALYSIS
    • 8.9.4. STRATEGIC INITIATIVES
  • 8.10. LEO PHARMA
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SWOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES
  • 8.11. MEDA PHARMACEUTICALS (MYLAN N.V.)
    • 8.11.1. COMPANY OVERVIEW
    • 8.11.2. PRODUCT PORTFOLIO
    • 8.11.3. SWOT ANALYSIS
    • 8.11.4. STRATEGIC INITIATIVES
  • 8.12. NOVARTIS AG
    • 8.12.1. COMPANY OVERVIEW
    • 8.12.2. PRODUCT PORTFOLIO
    • 8.12.3. SWOT ANALYSIS
    • 8.12.4. STRATEGIC INITIATIVES
  • 8.13. PFIZER
    • 8.13.1. COMPANY OVERVIEW
    • 8.13.2. PRODUCT PORTFOLIO
    • 8.13.3. SWOT ANALYSIS
    • 8.13.4. STRATEGIC INITIATIVES
  • 8.14. REGENERON PHARMACEUTICALS
    • 8.14.1. COMPANY OVERVIEW
    • 8.14.2. PRODUCT PORTFOLIO
    • 8.14.3. SWOT ANALYSIS
    • 8.14.4. STRATEGIC INITIATIVES
  • 8.15. SANOFI SA
    • 8.15.1. COMPANY OVERVIEW
    • 8.15.2. PRODUCT PORTFOLIO
    • 8.15.3. SWOT ANALYSIS
    • 8.15.4. STRATEGIC INITIATIVES
  • 8.16. VALENT PHARMACEUTICAL INC.
    • 8.16.1. COMPANY OVERVIEW
    • 8.16.2. PRODUCT PORTFOLIO
    • 8.16.3. SWOT ANALYSIS

TABLE LIST

  • TABLE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
  • TABLE 3 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
  • TABLE 4 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)
  • TABLE 5 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)
  • TABLE 15 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)
  • TABLE 17 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)
  • TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
  • TABLE 20 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

FIGURES LIST

  • FIGURE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 GERMANY ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 3 FRANCE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 4 THE UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 5 RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 6 ITALY ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 7 REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
Back to Top